EX-99.1

Exhibit 99.1

LOGO

ASX/Media Release

Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting

•	New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma

•	Deep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months)

•	In the overall patient population, regardless of PD-L1 expression, a strong response rate of 29.7% and 12-month overall survival rate of 46.0% were achieved

•	In patients with a PD-L1 Combined Positive Score of ≥20, a very promising response rate of 60% and 12-month overall survival rate of 66.7% were achieved

•	Treatment was safe and well tolerated with no new safety signals

•	More mature and final data will be presented during the poster session at ASCO 2023

SYDNEY, AUSTRALIA – 26 May 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces data from Part C of its TACTI-002 Phase II trial has been published in an abstract available on the 2023 American Society of Clinical Oncology’s (ASCO) Annual Meeting’s official website. A Trial in Progress abstract for the Phase II/III AIPAC-003 trial has also been published.

The TACTI-002 poster will contain more mature (longer follow up) and final data that is not part of the abstract and will be available on the Posters & Publication section of Immutep’s website after its presentation at ASCO. Abstracts are available at ASCO.org.

TACTI-002 Abstract

Title: Final results from TACTI-002 Part C: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1

Poster Session: Head and Neck Cancer

Date and Time: 5 June 2023, 2:15PM-5:15PM EDT

Presenter: Dr. Bernard Doger, START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain

Abstract #: 6029

AIPAC-003 Abstract

Title: AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization.

Poster Session: Breast Cancer – Local/Regional/Adjuvant

Date and Time: 4 June 2023, 9:00AM-12:00PM EDT

Presenter: Dr. Nuhad K. Ibrahim, Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract #: TPS1120